Publications

  1. Shinohara M, Fujioka S, Murray ME, Wojtas A, Baker M, Rovelet-Lecrux A, Rademakers R, Das P, Parisi JE, Graff-Radford NR, Petersen RC, Dickson DW, Bu G. Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease. Brain. 2014 May; 137(Pt 5):1533-49. Epub 2014 Mar 12.
    View PubMed
  2. Born HA, Kim JY, Savjani RR, Das P, Dabaghian YA, Guo Q, Yoo JW, Schuler DR, Cirrito JR, Zheng H, Golde TE, Noebels JL, Jankowsky JL. Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzeimer's disease. J Neurosci. 2014 Mar 12; 34(11):3826-40.
    View PubMed
  3. Chen F, Radisky ES, Das P, Batra J, Hata T, Hori T, Baine AM, Gardner L, Yue MY, Bu G, del Zoppo G, Patel TC, Nguyen JH. TIMP-1 attenuates blood-brain barrier permeability in mice with acute liver failure. J Cereb Blood Flow Metab. 2013 Jul; 33(7):1041-9. Epub 2013 Mar 27.
    View PubMed
  4. d'Uscio LV, Das P, Santhanam AV, He T, Younkin SG, Katusic ZS. Activation of PPARdelta prevents endothelial dysfunction induced by overexpression of amyloid-beta precursor protein. Cardiovasc Res. 2012 Dec 1; 96(3):504-12. Epub 2012 Aug 10.
    View PubMed
  5. Rademakers R, Baker M, Nicholson AM, Rutherford NJ, Finch N, Soto-Ortolaza A, Lash J, Wider C, Wojtas A, DeJesus-Hernandez M, Adamson J, Kouri N, Sundal C, Shuster EA, Aasly J, MacKenzie J, Roeber S, Kretzschmar HA, Boeve BF, Knopman DS, Petersen RC, Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet. 2012 Feb; 44(2):200-5. Epub 2011 Dec 25.
    View PubMed
  6. Hanna A, Iremonger K, Das P, Dickson D, Golde T, Janus C. Age-related increase in amyloid plaque burden is associated with impairment in conditioned fear memory in CRND8 mouse model of amyloidosis. Alzheimers Res Ther. 2012; 4(3):21. Epub 2012 Jun 14.
    View PubMed
  7. Moore BD, Chakrabarty P, Levites Y, Kukar TL, Baine AM, Moroni T, Ladd TB, Das P, Dickson DW, Golde TE. Overlapping profiles of Abeta peptides in the Alzheimer's disease and pathological aging brains. Alzheimers Res Ther. 2012; 4(3):18. Epub 2012 May 23.
    View PubMed
  8. Verbeeck C, Deng Q, Dejesus-Hernandez M, Taylor G, Ceballos-Diaz C, Kocerha J, Golde T, Das P, Rademakers R, Dickson DW, Kukar T. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis. Mol Neurodegener. 2012; 7:53. Epub 2012 Oct 10.
    View PubMed
  9. Chakrabarty P, Tianbai L, Herring A, Ceballos-Diaz C, Das P, Golde TE. Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Mol Neurodegener. 2012; 7:36. Epub 2012 Jul 29.
    View PubMed
  10. D'Uscio LV, Das P, Santhanam AVR, He T, Younkin SG, Katusic ZS. Activation of PPAR delta prevents endothelial dysfunction induced by overexpression of amyloid-beta precursor protein. Cardiovasc Res. 2012; 96(3):504-12.
  11. Das P, Verbeeck C, Minter L, Chakrabarty P, Felsenstein K, Kukar T, Maharvi G, Fauq A, Osborne BA, Golde TE. Transient pharmacologic lowering of Abeta production prior to deposition results in sustained reduction of amyloid plaque pathology. Mol Neurodegener. 2012; 7:39. Epub 2012 Aug 14.
    View PubMed
  12. Rodgers SP, Born HA, Das P, Jankowsky JL. Transgenic APP expression during postnatal development causes persistent locomotor hyperactivity in the adult. Mol Neurodegener. 2012; 7:28. Epub 2012 Jun 18.
    View PubMed
  13. Kukar TL, Ladd TB, Robertson P, Pintchovski SA, Moore B, Bann MA, Ren Z, Jansen-West K, Malphrus K, Eggert S, Maruyama H, Cottrell BA, Das P, Basi GS, Koo EH, Golde TE. Lysine 624 of the amyloid precursor protein (APP) is a critical determinant of amyloid beta peptide length: support for a sequential model of gamma-secretase intramembrane proteolysis and regulation by the amyloid beta precursor protein (APP) juxtamembrane region. J Biol Chem. 2011 Nov 18; 286(46):39804-12. Epub 2011 Aug 25.
    View PubMed
  14. Chakrabarty P, Ceballos-Diaz C, Lin WL, Beccard A, Jansen-West K, McFarland NR, Janus C, Dickson D, Das P, Golde TE. Interferon-gamma induces progressive nigrostriatal degeneration and basal ganglia calcification. Nat Neurosci. 2011 Jun; 14(6):694-6. Epub 2011 May 15.
    View PubMed
  15. Wang A, Das P, Switzer RC 3rd, Golde TE, Jankowsky JL. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J Neurosci. 2011 Mar 16; 31(11):4124-36.
    View PubMed
  16. Chakrabarty P, Herring A, Ceballos-Diaz C, Das P, Golde TE. Hippocampal expression of murine TNFalpha results in attenuation of amyloid deposition in vivo. Mol Neurodegener. 2011; 6:16. Epub 2011 Feb 16.
    View PubMed
  17. Meckler X, Roseman J, Das P, Cheng H, Pei S, Keat M, Kassarjian B, Golde TE, Parent AT, Thinakaran G. Reduced Alzheimer's disease ss-amyloid deposition in transgenic mice expressing S-palmitoylation-deficient APH1aL and nicastrin. J Neurosci. 2010 Dec 1; 30(48):16160-9.
    View PubMed
  18. Chakrabarty P, Ceballos-Diaz C, Beccard A, Janus C, Dickson D, Golde TE, Das P. IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol. 2010 May 1; 184(9):5333-43. Epub 2010 Apr 05.
    View PubMed
  19. Chakrabarty P, Jansen-West K, Beccard A, Ceballos-Diaz C, Levites Y, Verbeeck C, Zubair AC, Dickson D, Golde TE, Das P. Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J. 2010 Feb; 24(2):548-59. Epub 2009 Oct 13.
    View PubMed
  20. Meckler X, Roseman J, Das P, Cheng H, Pei S, Keat M, Kassarjian B, Golde TE, Parent AT, Thinakaran G. Reduced Alzheimer's disease beta-amyloid deposition in transgenic mice expressing S-palmitoylation-deficient APH1aL and nicastrin. J Neurosci. 2010; 30(48):16160-9.
  21. McAlpine FE, Lee JK, Harms AS, Ruhn KA, Blurton-Jones M, Hong J, Das P, Golde TE, LaFerla FM, Oddo S, Blesch A, Tansey MG. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis. 2009 Apr; 34(1):163-77.
    View PubMed
  22. Golde TE, Das P, Levites Y. Quantitative and mechanistic studies of Abeta immunotherapy. CNS Neurol Disord Drug Targets. 2009 Mar; 8(1):31-49.
    View PubMed
  23. Garcia-Alloza M, Subramanian M, Thyssen D, Borrelli LA, Fauq A, Das P, Golde TE, Hyman BT, Bacskai BJ. Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575. Mol Neurodegener. 2009; 4:19. Epub 2009 May 06.
    View PubMed
  24. Samon JB, Champhekar A, Minter LM, Telfer JC, Miele L, Fauq A, Das P, Golde TE, Osborne BA. Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells. Blood. 2008 Sep 1; 112(5):1813-21. Epub 2008 Jun 11.
    View PubMed
  25. Spilman P, Lessard P, Sattavat M, Bush C, Tousseyn T, Huang EJ, Giles K, Golde T, Das P, Fauq A, Prusiner SB, Dearmond SJ. A gamma-secretase inhibitor and quinacrine reduce prions and prevent dendritic degeneration in murine brains. Proc Natl Acad Sci U S A. 2008 Jul 29; 105(30):10595-600. Epub 2008 Jul 22.
    View PubMed
  26. Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T, Masliah E, Roberts AR, Bartfai T. Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci U S A. 2008 Feb 19; 105(7):2681-6. Epub 2008 Feb 12.
    View PubMed
  27. Fauq AH, Simpson K, Maharvi GM, Golde T, Das P. A multigram chemical synthesis of the gamma-secretase inhibitor LY411575 and its diastereoisomers. Bioorg Med Chem Lett. 2007 Nov 15; 17(22):6392-5. Epub 2007 Aug 30.
    View PubMed
  28. Li T, Wen H, Brayton C, Das P, Smithson LA, Fauq A, Fan X, Crain BJ, Price DL, Golde TE, Eberhart CG, Wong PC. Epidermal growth factor receptor and notch pathways participate in the tumor suppressor function of gamma-secretase. J Biol Chem. 2007 Nov 2; 282(44):32264-73. Epub 2007 Sep 07.
    View PubMed
  29. Lawlor PA, Bland RJ, Das P, Price RW, Holloway V, Smithson L, Dicker BL, During MJ, Young D, Golde TE. Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels. Mol Neurodegener. 2007; 2:11 Epub 2007 Jun 9.
    View PubMed
  30. Levites Y, Smithson LA, Price RW, Dakin RS, Yuan B, Sierks MR, Kim J, McGowan E, Reed DK, Rosenberry TL, Das P, Golde TE. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. FASEB J. 2006 Dec; 20(14):2576-8. Epub 2006 Oct 26.
    View PubMed
  31. Levites Y, Jansen K, Smithson LA, Dakin R, Holloway VM, Das P, Golde TE. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J Neurosci. 2006 Nov 15; 26(46):11923-8.
    View PubMed
  32. Maier M, Seabrook TJ, Lazo ND, Jiang L, Das P, Janus C, Lemere CA. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J Neurosci. 2006 May 3; 26(18):4717-28.
    View PubMed
  33. Head E, Barrett EG, Murphy MP, Das P, Nistor M, Sarsoza F, Glabe CC, Kayed R, Milton S, Vasilevko V, Milgram NW, Agadjanyan MG, Cribbs DH, Cotman CW. Immunization with fibrillar Abeta(1-42) in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Abeta. Vaccine. 2006 Apr 5; 24(15):2824-34. Epub 2006 Jan 19.
    View PubMed
  34. Levites Y, Das P, Price RW, Rochette M, Kostura, LA, McGowan E, Murphy MP, Golde TE. Anti-Aβ42 and Anti-Aβ40 specific monoclonal antibodies attenuate amyloid deposition in an Alzheimer’s disease mouse model. J Clin Invest. 2006 Jan; 116(1):193-201.
  35. Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest. 2006 Jan; 116(1):193-201. Epub 2005 Dec 08.
    View PubMed
  36. Das P, Smithson LA, Price RW, Holloway VM, Levites Y, Chakrabarty P, Golde TE. Interleukin-1 receptor 1 knockout has no effect on amyloid deposition in Tg2576 mice and does not alter efficacy following Abeta immunotherapy. J Neuroinflammation. 2006; 3:17. Epub 2006 Jul 26.
    View PubMed
  37. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, Delucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005 Jul 21; 47(2):191-9.
    View PubMed
  38. Minter LM, Turley DM, Das P, Shin HM, Joshi I, Lawlor RG, Cho OH, Palaga T, Gottipati S, Telfer JC, Kostura L, Fauq AH, Simpson K, Such KA, Miele L, Golde TE, Miller SD, Osborne BA. Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. Nat Immunol. 2005 Jul; 6(7):680-8.
    View PubMed
  39. Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, Dodson M, Merit S, Ozols VV, Anastasiadis PZ, Das P, Fauq A, Koo EH, Golde TE. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med. 2005 May; 11(5):545-50. Epub 2005 Apr 17.
    View PubMed
  40. Head E, Moffat K, Das P, Sarsoza E, Poon WW, Landsberg G, Cotman CW, Murphy MP. beta-amyloid deposition and tau phosphorylation in clinically characterized aged cats. Neurobiol Aging. 2005 May; 26(5):749-63.
    View PubMed
  41. Das P, Chapoval S, Howard V, David CS, Golde TE. Immune responses against Abeta1-42 in HLA class II transgenic mice: implications for Abeta1-42 immune-mediated therapies. Neurobiol Aging. 2003 Nov; 24(7):969-76.
    View PubMed
  42. Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci. 2003 Sep 17; 23(24):8532-8.
    View PubMed
  43. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003 Aug; 112(3):440-9.
    View PubMed
  44. Murphy MP, Das P, Nyborg AC, Rochette MJ, Dodson MW, Loosbrock NM, Souder TM, McLendon C, Merit SL, Piper SC, Jansen KR, Golde TE. Overexpression of nicastrin increases Abeta production. FASEB J. 2003 Jun; 17(9):1138-40. Epub 2003 Apr 08.
    View PubMed
  45. Das P, Chapoval S, Howard V, David CS, Golde TE. Immune responses against Aβ1-42 in HLA class II transgenic mice: Implications for Aβ1-42 immune-mediated therapies. Neurobiol Aging. 2003; 24:893-1019.
  46. Wahrle S, Das P, Nyborg AC, McLendon C, Shoji M, Kawarabayashi T, Younkin LH, Younkin SG, Golde TE. Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis. 2002 Feb; 9(1):11-23.
    View PubMed
  47. Wahrle S, Das P, Nyborg AC, McLendon DC, Shoji M, Kawarabayashi T, Younkin LH, Younkin, SG, Golde TE. Cholesterol dependent γ-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis. 2002; 9(1):11-23.
  48. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001 Nov 8; 414(6860):212-6.
    View PubMed
  49. Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging. 2001 Sep-Oct; 22(5):721-7.
    View PubMed
  50. Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE. Reduced effectiveness of Aβ 1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging. 2001; 22:721-7.
  51. Das P, Drescher KM, Geluk A, Bradley DS, Rodriguez M, David CS. Complementation between specific HLA-DR and HLA-DQ genes in transgenic mice determines susceptibility to experimental autoimmune encephalomyelitis. Hum Immunol. 2000 Mar; 61(3):279-89.
    View PubMed
  52. Das P, Abraham R, David C. HLA transgenic mice as models of human autoimmune diseases. Rev Immunogenet. 2000; 2(1):105-14.
    View PubMed
  53. Das P, Bradley DS, Geluk A, Griffiths MM, Luthra HS, David CS. An HLA-DRB1*0402 derived peptide (HV3 65-79) prevents collagen-induced arthritis in HLA-DQ8 transgenic mice. Hum Immunol. 1999 Jul; 60(7):575-82.
    View PubMed
  54. Bradley DS, Das P, Griffiths MM, Luthra HS, David CS. HLA-DQ6/8 double transgenic mice develop auricular chondritis following type II collagen immunization: a model for human relapsing polychondritis. J Immunol. 1998 Nov 1; 161(9):5046-53.
    View PubMed
  55. Bradley DS, Das P, Griffiths MM, Luthra HS, David CS. HLA-DQ6/8double transgenic mice develop auricular chondritis following bovine type II collagen immunization. J Immunol. 1998; 161:5046-53.
  56. Chen S, Das P, Hussein MG, Hari V. Electron microscopic localization of ATPase activity in tobacco cells infected with TEV and TMV. Arch Virol. 1995; 140:173-8.
  57. Das P, Hari V. Monoclonal antibodies reactive with specific amino acid sequences to the 126K protein of TMV. Arch Virol. 1994; 137:179-83.
  58. Chen S, Das P, Hari V. In situ localization of ATPase activity in cells infected by Maize Dwarf Mosaic potyvirus. Arch Virol. 1994; 134:433-9.
  59. Das P, Hari V. Detection of antibodies to HIV p24/25 and gp 120 proteins using SLIDA. Biotechniques. 1993; 14(5):774-80.
  60. Das P, Hari V. Intracellular distribution of the 126K/183K and capsid proteins in cells infected by some tobamoviruses. J Gen Virol. 1992; 73:3039-43.
  61. Baunoch DA, Das P, Browning ME, Hari V. A temporal study of the capsid and three non-structural protein of TEV in infected plants. J Gen Virol. 1991; 72:487-92.
  62. Baunoch DA, Das P, Hari V. Potato virus Y helper component protein is associated with amorphous inclusions. J Gen Virol. 1990; 71:2479-80.
  63. Hari V, Baunoch DA, Das P. A sensitive Sphere Linked Immuno diagnostic Assay (SLIDA) for detection of antibodies to viruses and other pathogens. Biotechniques. 1990; 9(3):342-50.
  64. Hari V, Gadh IPS, Baunoch DA, Das P. BMMV; The genome and its translation products. Virus Genes. 1988; 2(3):211-21.